Stoke Therapeutics Reports Third-Quarter 2026 Results
Revenue rose 5.9% year over year to $11.3 million. Net loss widened to $73.6 million from $38.3 million, and diluted loss per share was $(1.08) versus $(0.65).
Stoke Therapeutics reported third-quarter 2026 revenue of $11.3 million, up 5.9% from the prior-year quarter, while its net loss widened to $73.6 million from $38.3 million and diluted loss per share was $(1.08), compared with $(0.65).Financial HighlightsBusiness HighlightsOriginal SEC Filing: Stok…